Scancell Doses First Subject in Coronavirus Vaccine Trial

Scancell Holdings PLC said Tuesday that it has dosed its first subject in its clinical trial for its Scov1 and Scov2 vaccine candidates, which aim to protect against all Covid-19 variants of concern. The biopharmaceutical company said that the first patient was dosed in South Africa as part of the program dubbed Covidity, and the candidate was administered using the PharmJet needle-free injection system. The objectives of the first part of the trial are to assess the safety and immunogenicity of Scov1 and Scov2, which target the original virus and variant viruses respectively, in healthy, non-vaccinated subjects.